CortevavsProto Labs

CTVA and PRLB stock compared: price, dividend, valuation and results, from SEC filings.

Over the last year, with dividends, CTVA moved -4.5% and PRLB +35.6%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CTVA–

    PRLB$1.6B

  • Revenue, 12 months

    CTVA$17.7B

    PRLB$579M

    CTVA is 30 times PRLB

  • Net income, 12 months

    CTVA$759M

    PRLB$35M

    CTVA is 22 times PRLB

  • Operating margin

    CTVA–

    PRLB7.3%

  • ROIC

    CTVA3.0%

    PRLB4.5%

    1.5 points apart

  • P/E

    CTVA–

    PRLB45.9

  • Dividend yield

    CTVA0.0%

    PRLB0.0%

    About the same

  • 5-year return

    CTVA+35.7%

    PRLB+14.0%

    21.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CTVA+35.7%

PRLB+14.0%

5010015020020222023202420252026
Returns by period
PeriodCTVAWith dividendsPRLBWith dividends
1 year since November 12, 2025-4.5%Price -5.4%+35.6%Price +35.6%
3 years since November 13, 2023+43.2%+12.7% a yearPrice +38.7%+92.6%+24.4% a yearPrice +92.6%
5 years since November 12, 2021+35.7%+6.3% a yearPrice +29.0%+14.0%+2.7% a yearPrice +14.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CTVACortevaPRLBProto Labs

Valuation

CTVAPRLB
Valuation
Price$9.43$67.55
Market value–$1.6B
Enterprise value (EV)–$1.5B
P/E–45.9
P/E, 5-year median41.958.3
P/B–2.3
EV/EBIT–34.3
Free cash flow yield–3.0%

Results and growth

CTVAPRLB
Results and growth
Revenue, 12 months$17.7B$579M
Net income, 12 months$759M$35M
Free cash flow, 12 months-$149M$49M
Earnings per share, 12 months$1.14$1.43
Revenue growth, year on year2.9%6.4%
Revenue growth a year, past+4.1%over 5 years+4.2%over 5 years
EPS growth a year, past+12.0%over 5 years-14.2%over 5 years

Margins and returns on capital

CTVAPRLB
Margins and returns on capital
Gross margin49.7%45.2%
Operating margin–7.3%
Net margin4.3%6.0%
ROIC3.0%4.5%
ROE3.1%5.1%

Balance sheet

CTVAPRLB
Balance sheet
Cash$3.9B$151M
Total debt$7.4B$3.9M
Net debt / EBITDA1.4-2.0
Interest cover6.7×–

Dividends and buybacks

CTVAPRLB
Dividends and buybacks
Dividend yield––
Dividend per share, 12 months$0.72–
Dividend growth a year, past+6.1%over 5 years–
Buyback yield–2.7%
Shareholder yield–2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CTVA or PRLB

Didn't find what you were looking for?

Ask us
How did CTVA and PRLB stock do over the last 5 years?

Since November 12, 2021, CTVA's price moved +29.0% and PRLB's +14.0%. With dividends: CTVA +35.7% (+6.3% a year), PRLB +14.0% (+2.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, CTVA or PRLB?

Neither paid a dividend over the last twelve months: Corteva and Proto Labs return money to shareholders, if they do, in other ways, such as buybacks.

Which has the higher profit margins, Corteva or Proto Labs?

Over the last twelve months, the net margin was 4.3% for Corteva and 6.0% for Proto Labs, and the operating margin – and 7.3%. Revenue was $17.7B and $579M.

Which is the better investment, Corteva or Proto Labs?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.